Comparison of Death Rates between COVID-19 Patients with Type 2 Diabetes Mellitus and without Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.24853/mmj.4.1.45-51Keywords:
covid-19, mortality, type 2 diabetes mellitusAbstract
Background: Coronavirus Disease 2019 (COVID-19) is an acute airway infection caused by coronavirus, and one of the comorbid diseases that can increase the severity and mortality of COVID-19 is diabetes mellitus. Purposes: To compare mortality rates in COVID-19 patients with type 2 DM and those without type 2 DM at Bunda Margonda General Hospital, Depok Jawa Barat. Methods: This study is a comparative study with a cross-sectional design obtained from secondary data in the form of medical record data at Bunda Margonda Depok Hospital in January-December 2021. The collection was carried out using the total sampling technique. Data were tested using the Cross Tabulation (crosstab) test. Results: Of the 144 COVID-19 patients, 56.9% of COVID-19 patients died with type 2 DM, while 43.1% died without type 2 DM comorbidity. Based on the comparison results of the mortality rate of COVID-19 patients accompanied by Type 2 DM and those not accompanied by Type 2 DM, the P value is 0.127, which means there was no relationship between mortality rate and Type 2 DM status. The mortality rate male gender is more likely to die in COVID-19 cases with an incidence of (53.5%), while in women (46.5%). Conclusion: Patients with comorbidities are more susceptible to Covid-19, and their symptoms are divided into mild, moderate, and severe. In patients with comorbid diabetes mellitus, there will be an increased occurrence of Covid-19 disease due to decreased immune function, resulting in a longer healing time in patients with diabetes mellitus.References
Lestari N, Ichsan B. Diabetes Melitus Sebagai Faktor Risiko Keparahan Dan Kematian Pasien Covid-19 : Meta-Analisis. Biomedika. 2020;13(1):83–94.
Syahniar R, Purba MB, Bekti HS, Mardhia M. Vaccines against coronavirus disease: target proteins, immune responses, and status of ongoing clinical trials. J Pure Appl Microbiol. 2020;14(4):2253–63.
Jaelani HF, Syahniar R. Factors associated with the willingness to receive COVID-19 vaccination among pregnant women. Int J Public Heal Sci. 2023 Mar 1;12(1):261.
Syahniar R, Kharisma DS. SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. Clin Exp Vaccine Res. 2022 May;11(2):173–83.
Hunafa AF, Harahap SP, Yulianti R, Nugraha Y. Hubungan Diabetes Melitus dengan Kejadian Mortalitas pada Pasien Terkonfirmasi Covid-19 Tahun 2020: Systematic Review. eJournal Kedokt Indones. 2021 May 5;9(1 SE-Review Article):67.
Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. Infodatin tetap produktif, cegah, dan atasi Diabetes Melitus. Kementerian Kesehatan Republik Indonesia; 2020 p. 1–10.
Uhm J-S, Ahn JY, Hyun J, Sohn Y, Kim JH, Jeong SJ, et al. Patterns of viral clearance in the natural course of asymptomatic COVID-19: Comparison with symptomatic non-severe COVID-19. Int J Infect Dis. 2020 Oct;99:279–85.
Roeroe PAL, Sedli BP, Umboh O. Faktor Risiko Terjadinya Coronavirus Disease 2019 (Covid-19) pada Penyandang Diabetes Melitus Tipe 2. e-CliniC. 2021;9(1):154–60.
Irsan A, Mardhia M, Rialita A. Evaluation of Humoral Response of Emergency Unit Healthcare Workers after Third Dose of COVID-19 Vaccination. Muhammadiyah Med J. 2022;3(1):27.
Adinagoro MR, Wiratama RB, Widyakusuma E.S Y, Humairah H, Navisa CC, Atika A. Mortalitas Pasien COVID-19 dengan Komorbiditas Diabetes Mellitus: Systematic Review. Aatomica Med J. 2021 Nov 4;4(3):170.
Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MenKes/413/2020 Tentang Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (Covid-19). 2020.
Widiastuti L. Acupressure dan Senam Kaki terhadap Tingkat Peripheral Arterial Disease pada Klien DM Tipe 2. J Keperawatan Silampari. 2020;3(2):694–706.
Drew C, Adisasmita AC. Gejala dan komorbid yang memengaruhi mortalitas pasien positif COVID-19 di Jakarta Timur, Maret-September 2020. Tarumanagara Med J. 2021 Apr 30;3(1):42–51.
Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021 Jan 13;17(1):11–30.
Afni N, Rahayu S. Analysis of Risk Factors for Death of Covid-19 Patients at Undata Hospital Palu. J Public Heal Pharm. 2021;1(6):110–5.
Norouzi M, Norouzi S, Ruggiero A, Khan MS, Myers S, Kavanagh K, et al. Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection. Microorganisms. 2021 Jun;9(6).
Hanis TM, Arifin WN, Musa KI, Rodzlan Hasani WS, Che Nawi CMNH, Shahrani SA, et al. Risk Factors for COVID-19 Mortality in Malaysia. Malays J Med Sci. 2022 Dec;29(6):123–31.
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020 May;318(5):E736–41.
Kim DW, Byeon KH, Kim J, Cho KD, Lee N. The Correlation of Comorbidities on the Mortality in Patients with COVID-19: an Observational Study Based on the Korean National Health Insurance Big Data. J Korean Med Sci. 2020 Jul;35(26):e243.
Downloads
Published
Issue
Section
License
Authors who publish in the Muhammadiyah Medical Journal agree to the following terms:
- Authors retain copyright and grant Muhammadiyah Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Licence that allows others to adapt (remix, transform, and build) upon the work non-commercially with an acknowledgement of the work's authorship and initial publication in Muhammadiyah Medical Journal.
- Authors are permitted to share (copy and redistribute) the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Muhammadiyah Medical Journal.
